Fenofibrate Contraindications
Fenofibrate is absolutely contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), active liver disease, preexisting gallbladder disease, nursing mothers, and those with known hypersensitivity to fenofibrate or fenofibric acid. 1
Absolute Contraindications
Based on FDA labeling and ACC/AHA guidelines, fenofibrate must not be used in the following situations:
Renal Contraindications
- Severe renal impairment (eGFR <30 mL/min/1.73 m²), including patients on dialysis 2, 1
- This is a Class III: Harm recommendation with Level of Evidence B 2
- If eGFR persistently decreases to <30 mL/min/1.73 m² during treatment, fenofibrate must be discontinued 2
Hepatobiliary Contraindications
- Active liver disease of any etiology 1
- Primary biliary cirrhosis 1
- Unexplained persistent liver function abnormalities 1
- Preexisting gallbladder disease 1
Other Absolute Contraindications
- Nursing mothers - fenofibrate is contraindicated during breastfeeding 1
- Known hypersensitivity to fenofibrate or fenofibric acid 1
Critical Relative Contraindications
Concomitant Gemfibrozil Use
- Gemfibrozil should never be initiated in patients on statin therapy due to increased risk of muscle symptoms and rhabdomyolysis 2
- This is a Class III: Harm recommendation with Level of Evidence B 2
Moderate Renal Impairment (eGFR 30-59 mL/min/1.73 m²)
- Not an absolute contraindication, but requires dose reduction to maximum 54 mg/day 2, 1
- Renal function must be evaluated before initiation, within 3 months, and every 6 months thereafter 2
- Despite guideline caution, research evidence from the FIELD study suggests fenofibrate can be used safely in moderate renal impairment with appropriate monitoring 3
Important Clinical Caveats
Renal function monitoring is mandatory - The ACC/AHA guidelines emphasize that both serum creatinine and eGFR must be assessed, as fenofibrate predictably increases creatinine levels (typically 7.9 mL/min/1.73 m² reduction in eGFR) 2, 4. This increase is generally reversible upon discontinuation 5, 6.
Statin combination therapy requires careful consideration - Fenofibrate may only be considered with low- or moderate-intensity statins (not high-intensity) when benefits outweigh risks, particularly for triglycerides >500 mg/dL 2. This is a Class IIb recommendation, meaning the benefit is uncertain.
Gender considerations - Post-hoc analysis from the ACCORD trial showed women without dyslipidemia may have increased cardiovascular risk with fenofibrate, though this finding requires confirmation 7, 1.
The evidence consistently shows these contraindications are based on safety concerns including rhabdomyolysis risk (with gemfibrozil), reversible but significant renal function changes, hepatotoxicity potential, and increased gallstone formation 1, 5, 8, 9.